Traws Pharma, Inc. entered into Purchase Agreement with the purchasers named therein valued at approximately $10,000,000 (effective 2026-04-15).
“On April 15, 2026, Traws Pharma, Inc. (the “Company”) announced the pricing of an offering (the “Private Placement”) of an aggregate of (i) 5,982,919 shares (the “Purchased Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”) (or, in lieu of Purchased Shares, pre-funded warrants to purchase shares of Common Stock (“Pre-Funded Warrants”)), (ii) Series A warrants to initially purchase up to 5,982,919 shares of Common Stock (the “Series A Warrants”), (iii) Series B warrants to initially purchase up to 5,982,919 shares of Common Stock (the “Series B Warrants”), and (iv) Series C warrants to initially purchase up to 17,948,757 shares of Common Stock (the “Series C Warrants” and together with the Pre-Funded Warrants, the Series A Warrants and the Series B Warrants, the “Warrants”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) by and between the Company and the purchasers named therein (the “Investors”).”
M&A Transactions
Traws Pharma, Inc. completed an acquisition involving Virom, Inc. for $2,350,000 in cash (closed 2025-09-09).
“On September 9, 2025, Traws Pharma, Inc. (the “Company”) and Virom, Inc. (“Viriom”) entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company purchased certain assets (the “Purchased Assets”) from Viriom in exchange for $2,350,000 in cash (the “Purchase Price”), which was paid in full to Virom on September 9, 2025.”
Iain Dukes was appointed as Interim Chief Executive Officer at Traws Pharma, Inc..
“Effective as of the Termination Date, the Board appointed Iain Dukes to serve as the Company’s Interim Chief Executive Officer.”
Werner Cautreels resigned as Chief Executive Officer at Traws Pharma, Inc..
“On March 28, 2025, Werner Cautreels notified Traws Pharma, Inc. (the Company”) of his decision to retire and resign from his role as Chief Executive Officer of the Company, effective as of the close of business on the day that the Company files its Annual Report on Form 10-K for its 2024 fiscal year”
Nora Brennan was appointed as Interim Chief Financial Officer at Traws Pharma, Inc..
“On February 5, 2025, the Company’s Board of Directors appointed Nora Brennan as the Company’s Interim Chief Financial Officer.”
Mark Guerin resigned as Chief Financial Officer at Traws Pharma, Inc..
“On February 5, 2025 (the “Termination Date”), Mark Guerin resigned from his position as the Chief Financial Officer of Traws Pharma, Inc.”
Luba Greenwood was appointed as Director at Traws Pharma, Inc..
“the Board appointed Luba Greenwood to the Board to fill the vacancy created by Mr. Marino’s resignation with a term expiring at the Company’s 2024 annual meeting of stockholders.”
James J. Marino resigned as Director at Traws Pharma, Inc..
“On September 16, 2024, James J. Marino, a member of the Board of Directors (the “Board”) of Traws Pharma, Inc. (the “Company”), resigned as a director.”
Steven M. Fruchtman resigned as President and Chief Scientific Officer, Oncology at Traws Pharma, Inc..
“On June 17, 2024, Steven M. Fruchtman informed the board of directors (the “Board”) of Traws Pharma, Inc. (the “Company”) of his intent to resign from his positions of President and Chief Scientific Officer, Oncology.”
Earnings Releases
Traws Pharma, Inc. reported the first quarter of 2024 results: revenue fifty-six thousand dollars, net income $5.0 million, or $0.24 per share, EPS $0.24 per share.
“Revenue was fifty-six thousand dollars for the first quarter of 2024, consistent with the same period in 2023.”
Governance Changes
Traws Pharma, Inc.: Changed company name to Traws Pharma, Inc. via certificate of amendment to Tenth Amended and Restated Certificate of Incorporation on April 2, 2024 (effective 2024-04-02).
“On April 2, 2024, the Company changed its name to Traws Pharma, Inc. pursuant to a certificate of amendment to its Tenth Amended and Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware (the “Name Change”).”
Governance Changes
Traws Pharma, Inc.: Filed Certificate of Designation for Series C Non-Voting Convertible Preferred Stock on April 1, 2024 (effective 2024-04-01).
“On April 1, 2024, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series C Non-Voting Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware in connection with the Merger referenced in Item 1.01 above.”
M&A Transactions
Traws Pharma, Inc. completed an acquisition involving Trawsfynydd Therapeutics, Inc. for 3,549,538 shares of common stock and 10,359.0916 shares of Series C Preferred Stock (closed 2024-04-01).
“shares of capital stock of Trawsfynydd immediately prior to the effective time of the First Merger, the Company issued to the stockholders of Trawsfynydd an aggregate of (A) 3,549,538 shares of common stock of the Company, par value $0.01 per share (the “Common Stock”) and (B) 10,359.0916 shares of Series C Preferred Stock (as defined and described below). Each”
Robert Redfield was appointed as Chief Medical Officer at Traws Pharma, Inc..
“In addition, effective immediately upon the Closing, C. David Pauza was appointed the Company’s Chief Scientific Officer, Virology and Robert Redfield was appointed the Company’s Chief Medical Officer.”
C. David Pauza was appointed as Chief Scientific Officer, Virology at Traws Pharma, Inc..
“In addition, effective immediately upon the Closing, C. David Pauza was appointed the Company’s Chief Scientific Officer, Virology and Robert Redfield was appointed the Company’s Chief Medical Officer.”
Werner Cautreels was appointed as Chief Executive Officer at Traws Pharma, Inc..
“appointed Werner Cautreels as the Company’s CEO and Nikolay Savchuk as the Company’s COO”
Nikolay Savchuk was appointed as Chief Operating Officer at Traws Pharma, Inc..
“appointed Werner Cautreels as the Company’s CEO and Nikolay Savchuk as the Company’s COO”
Iain Dukes was appointed as Executive Chairman at Traws Pharma, Inc..
“appointed Iain Dukes as a director and Executive Chairman of the Company”
Mark Guerin departed as Chief Financial Officer at Traws Pharma, Inc..
“Mark Guerin remained as the Chief Financial Officer of the Company”
Steven M. Fruchtman was appointed as President and Chief Scientific Officer, Oncology at Traws Pharma, Inc..
“Dr. Steven M. Fruchtman remained as the President of the Company and was appointed Chief Scientific Officer, Oncology”
Viren Mehta resigned as Director at Traws Pharma, Inc..
“accepted the resignations of Dr. Steven M. Fruchtman, Peter Atadja, Jerome Groopman, and Viren Mehta from the Board”
Jerome Groopman resigned as Director at Traws Pharma, Inc..
“accepted the resignations of Dr. Steven M. Fruchtman, Peter Atadja, Jerome Groopman, and Viren Mehta from the Board”
Peter Atadja resigned as Director at Traws Pharma, Inc..
“accepted the resignations of Dr. Steven M. Fruchtman, Peter Atadja, Jerome Groopman, and Viren Mehta from the Board”
Steven M. Fruchtman resigned as Director at Traws Pharma, Inc..
“accepted the resignations of Dr. Steven M. Fruchtman, Peter Atadja, Jerome Groopman, and Viren Mehta from the Board”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.